GlaxoSmithKline's (GSK +0.1%) lung treatment Relovair proved successful in two six-month phase...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline's (GSK +0.1%) lung treatment Relovair proved successful in two six-month phase III trials. GSK and partner Theravance (THRX -1.6%) hope Relovair will generate billions of dollars, but will wait for results from larger 12-month studies before filing for approval. (PR)